# US 2009/0022687 A1 · Novel Pharmaceuticals That Use Anti-HLA Antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0022687 A1
- Document ID: US20090022687A1
- Status: Published application
- Kind: A1
- Application number: 11/913,229
- Filed: 2006-05-18
- Published: 2009-01-22
- Earliest claimed: 2005-05-18
- Assignees: Chugai Seiyaku Kabushiki Kaisha; The University of Tokushima
- Inventors: Toshio Matsumoto; Shuji Ozaki; Masahiro Abe
- Web page: https://patentgrep.com/patent/US20090022687A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61K 38/212: {IFN-alpha}
- A61K 38/217: {IFN-gamma}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 17/06: Antipsoriatics
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present inventors tested the effects of interferons on the expression of HLA-A in cells and cell injury caused by anti-HLA class I antibodies, by using a 2D7-DB antibody as an anti-HLA class I antibody and the IM-9 cell line as the cells to be tested. As a result, the expression of HLA-A was demonstrated to be upregulated by IFNα or IFNγ, Furthermore, WST-8 assays were performed to examine the cell viability when an interferon and an anti-HLA class I antibody were used in combination. As a result, cell death activity was found to be increased by the combination of 2D7-DB and IFNα or IFNγ.

## Claims

### Claim 1

A pharmaceutical composition comprising an interferon and an anti-HLA class I antibody as active ingredients.

### Claim 2

A pharmaceutical composition comprising an anti-HLA class I antibody as an active ingredient, wherein the composition is used in combination with an interferon.

### Claim 3

A pharmaceutical composition comprising an anti-HLA class I antibody as an active ingredient, wherein the composition is administered simultaneously with an interferon.

### Claim 4

A pharmaceutical composition comprising an anti-HLA class I antibody as an active ingredient, wherein the composition is administered after administration of an interferon.

### Claim at position 5

5-13. (canceled)

### Claim 14

A method of treating or preventing a tumor in a patient, the method comprising administering to the patient an anti-HLA class I antibody and an interferon.

### Claim 15 (depends on 14)

The method of claim 14, wherein the anti-HLA class I antibody and the interferon are administered simultaneously.

### Claim 16 (depends on 14)

The method of claim 14, wherein the anti-HLA class I antibody is administered after the interferon has been administered.

### Claim 17 (depends on 14)

The method of claim 14, wherein the anti-HLA class I antibody is an anti-HLA-A antibody.

### Claim 18 (depends on 14)

The method of claim 14, wherein the anti-HLA class I antibody is a minibody.

### Claim 19

A method of treating or preventing an autoimmune disease in a patient, the method comprising administering to the patient an anti-HLA class I antibody and an interferon.

### Claim 20 (depends on 19)

The method of claim 19, wherein the anti-HLA class I antibody and the interferon are administered simultaneously.

### Claim 21 (depends on 19)

The method of claim 19, wherein the anti-HLA class I antibody is administered after the interferon has been administered.

### Claim 22 (depends on 19)

The method of claim 19, wherein the anti-HLA class I antibody is an anti-HLA-A antibody.

### Claim 23 (depends on 19)

The method of claim 19, wherein the anti-HLA class I antibody is a minibody.

### Claim 24

A method of inducing death of a cell, the method comprising administering to the cell an anti-HLA class I antibody and an interferon.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cell is in a patient.

### Claim 26 (depends on 24)

The method of claim 24, wherein the anti-HLA class I antibody and the interferon are administered simultaneously.

### Claim 27 (depends on 24)

The method of claim 24, wherein the anti-HLA class I antibody is administered after the interferon has been administered.

### Claim 28 (depends on 24)

The method of claim 24, wherein the anti-HLA class I antibody is an anti-HLA-A antibody.

### Claim 29 (depends on 24)

The method of claim 24, wherein the anti-HLA class I antibody is a minibody.

### Claim 30

A method of enhancing an action of an anti-HLA class I antibody, the method comprising administering the anti-HLA class I antibody and an interferon to a cell.

### Claim 31 (depends on 30)

The method of claim 30, wherein the cell is in a patient.
